GENEVA (AP) -- Swiss drugmaker Roche Holding AG has reported a 6 percent increase in overall sales for the first nine months of 2012, based on demand for its cancer drugs.
The Basel, Switzerland-based company says its group sales over three quarters rose to 34.9 billion Swiss francs ($38.2 billion), up from 33.7 billion francs in the same time period last year.
The world's biggest producer of cancer-fighting drugs said Thursday it had strong growth in the third quarter from sales of cancer medicines Avastin, Herceptin, MabThera/Rituxan, Perjeta and Kadcyla, as well as rheumatoid arthritis treatment Actemra/RoActemra.
Roche CEO Severin Schwan said before the opening of the Zurich exchange the company "will meet our full-year targets" and he was encouraged by the uptake of new drugs Perjeta and Kadcyla.
- Health Care Industry
- Roche Holding AG
- cancer drugs